loading
Precedente Chiudi:
$46.84
Aprire:
$46.92
Volume 24 ore:
47.28M
Relative Volume:
3.34
Capitalizzazione di mercato:
$101.69B
Reddito:
$47.64B
Utile/perdita netta:
$5.42B
Rapporto P/E:
17.55
EPS:
2.67
Flusso di cassa netto:
$13.09B
1 W Prestazione:
-5.81%
1M Prestazione:
-2.11%
6M Prestazione:
-18.26%
1 anno Prestazione:
+14.18%
Intervallo 1D:
Value
$46.72
$47.40
Intervallo di 1 settimana:
Value
$46.39
$49.44
Portata 52W:
Value
$39.35
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Nome
Bristol Myers Squibb Co
Name
Telefono
(609) 252-4621
Name
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Dipendente
34,100
Name
Cinguettio
@BMSNEWS
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BMY's Discussions on Twitter

Confronta BMY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
46.86 101.69B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.73 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
149.79 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
73.77 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.30 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.77 234.21B 53.22B 12.86B 14.85B 6.39

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-04-22 Iniziato Piper Sandler Overweight
2024-12-16 Aggiornamento Jefferies Hold → Buy
2024-12-10 Ripresa BofA Securities Neutral
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-13 Aggiornamento Daiwa Securities Neutral → Outperform
2024-11-12 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-25 Downgrade Citigroup Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-07-29 Downgrade Barclays Overweight → Equal Weight
2024-03-11 Downgrade Societe Generale Buy → Hold
2024-02-06 Downgrade Redburn Atlantic Buy → Neutral
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-02 Downgrade Daiwa Securities Outperform → Neutral
2023-10-27 Downgrade BMO Capital Markets Outperform → Market Perform
2023-10-27 Aggiornamento HSBC Securities Reduce → Hold
2023-10-27 Downgrade William Blair Outperform → Mkt Perform
2023-10-20 Ripresa UBS Neutral
2023-07-14 Iniziato HSBC Securities Reduce
2023-07-10 Iniziato SVB Securities Market Perform
2023-06-28 Iniziato Daiwa Securities Outperform
2023-03-06 Iniziato Jefferies Hold
2023-01-17 Iniziato Cantor Fitzgerald Overweight
2022-11-18 Iniziato Credit Suisse Neutral
2022-10-10 Downgrade Guggenheim Buy → Neutral
2022-09-14 Downgrade Berenberg Buy → Hold
2022-06-03 Downgrade Raymond James Outperform → Mkt Perform
2022-04-06 Ripresa Morgan Stanley Underweight
2021-12-17 Iniziato Goldman Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-11-01 Downgrade Argus Buy → Hold
2021-07-27 Ripresa Truist Buy
2021-04-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-04-13 Aggiornamento Truist Hold → Buy
2020-11-16 Aggiornamento Societe Generale Hold → Buy
2020-11-10 Ripresa Bernstein Mkt Perform
2020-11-06 Downgrade Gabelli & Co Buy → Hold
2020-10-19 Aggiornamento Guggenheim Neutral → Buy
2020-09-29 Iniziato Berenberg Buy
2020-07-28 Iniziato Raymond James Outperform
2020-04-02 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-01-06 Ripresa Citigroup Buy
2019-12-13 Aggiornamento Argus Hold → Buy
2019-11-22 Ripresa Morgan Stanley Equal-Weight
2019-10-17 Ripresa BofA/Merrill Buy
2019-08-14 Aggiornamento Atlantic Equities Neutral → Overweight
2019-05-28 Iniziato Goldman Buy
2019-05-20 Downgrade Argus Buy → Hold
2019-05-03 Aggiornamento Barclays Equal Weight → Overweight
2019-05-03 Ripresa JP Morgan Overweight
2019-01-15 Aggiornamento Societe Generale Sell → Buy
2018-10-22 Downgrade Citigroup Buy → Neutral
Mostra tutto

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb Announces Dividend - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers: positive phase 2 data in lymphoma - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews

Jun 16, 2025
pulisher
Jun 16, 2025

Business development leadership team - Bristol Myers Squibb

Jun 16, 2025
pulisher
Jun 16, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com

Jun 14, 2025
pulisher
Jun 14, 2025

Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News

Jun 13, 2025
pulisher
Jun 12, 2025

Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360

Jun 12, 2025
pulisher
Jun 12, 2025

BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers: new data to be presented in hematology - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe

Jun 12, 2025
pulisher
Jun 11, 2025

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq

Jun 11, 2025

Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Bristol Myers Squibb Co Azioni (BMY) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Hickey Benjamin
President, RayzeBio Org.
May 09 '25
Sale
38.01
97
3,702
0
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
Apr 25 '25
Buy
47.58
4,250
202,215
83,513
Shanahan Karin
EVP, Glob. Prod. Dev. & Supply
Apr 01 '25
Option Exercise
0.00
3,306
0
15,489
Plenge Robert M
EVP, Chief Research Officer
Mar 10 '25
Option Exercise
0.00
11,255
0
20,148
Meyers Gregory Scott
EVP, Chief Digital & Tech Off.
Mar 10 '25
Option Exercise
0.00
23,150
0
26,937
Shanahan Karin
EVP, Glob. Prod. Dev. & Supply
Mar 10 '25
Option Exercise
0.00
20,423
0
22,339
Lenkowsky Adam
EVP, Chief Commercial Officer
Mar 10 '25
Option Exercise
0.00
16,684
0
20,017
Poole Ahn Amanda
EVP, Chief People Officer
Mar 10 '25
Option Exercise
0.00
7,164
0
8,546
LEUNG SANDRA
EVP, General Counsel
Mar 10 '25
Option Exercise
0.00
48,718
0
386,496
Hoch Lynelle
President, Cell Therapy Org.
Mar 10 '25
Option Exercise
0.00
7,446
0
7,920
drug_manufacturers_general SNY
$47.86
price up icon 0.50%
$108.50
price up icon 0.46%
drug_manufacturers_general PFE
$23.97
price up icon 0.38%
$289.33
price down icon 0.10%
drug_manufacturers_general MRK
$79.06
price down icon 0.29%
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
Capitalizzazione:     |  Volume (24 ore):